Current Report Filing (8-k)
September 01 2021 - 5:28PM
Edgar (US Regulatory)
0001175151
false
0001175151
2021-08-30
2021-08-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported):
August 30, 2021
CYTOSORBENTS CORPORATION
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-36792
|
|
98-0373793
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification No.)
|
7 Deer Park Drive, Suite K,
Monmouth Junction, New Jersey
|
08852
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (732) 329-8885
Not Applicable
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
common stock, $0.001 par value
|
CTSO
|
The Nasdaq Stock Market LLC (Nasdaq Capital Market)
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company ¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
On August 30, 2021, CytoSorbents
Corporation (the “Company”) and Aferetica srl (Italy) issued a press release announcing the commercial launch of Aferetica’s
PerLife™ ex vivo organ perfusion system for kidney and liver transplant and CytoSorbents’ PerSorb™ adsorber, based on
the CytoSorbents ECOS-300CY™ sorbent technology to remove inflammatory mediators during ex vivo organ perfusion, at the European
Society of Organ Transplantation (ESOT) Congress in Milan, Italy from August 29–September 1, 2021. A copy of the press release is
attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.
On September 1, 2021, the
Company issued a press release announcing that topline results from its CytoSorb Therapy in COVID-19 (CTC) multicenter registry were presented
at the 40th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2021) in Brussels, Belgium on August 31, 2021. A
copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and incorporated by reference herein.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: September 1, 2021
|
CYTOSORBENTS CORPORATION
|
|
|
|
|
By:
|
/s/ Dr. Phillip P. Chan
|
|
Name:
|
Dr. Phillip P. Chan
|
|
Title:
|
Chief Executive Officer
|
CytoSorbents (NASDAQ:CTSO)
Historical Stock Chart
From Aug 2024 to Sep 2024
CytoSorbents (NASDAQ:CTSO)
Historical Stock Chart
From Sep 2023 to Sep 2024